- Report
- January 2022
- 200 Pages
Global
From €7163EUR$7,500USD£5,990GBP
- Report
- January 2022
- 60 Pages
Global
From €3772EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3772EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3772EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3772EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3772EUR$3,950USD£3,155GBP
- Report
- July 2019
Global
From €955EUR$1,000USD£799GBP
- Report
- April 2023
- 124 Pages
Global
From €4536EUR$4,750USD£3,794GBP
- Report
- September 2023
- 200 Pages
Global
From €3437EUR$3,599USD£2,874GBP
- Report
- April 2023
- 147 Pages
Global
From €4726EUR$4,949USD£3,953GBP
- Report
- January 2024
- 200 Pages
Global
From €3963EUR$4,150USD£3,314GBP
- Report
- December 2023
- 160 Pages
Global
From €2388EUR$2,500USD£1,997GBP
- Report
- February 2024
- 110 Pages
Global
From €4536EUR$4,750USD£3,794GBP
- Report
- January 2022
- 112 Pages
Global
From €4536EUR$4,750USD£3,794GBP
- Report
- January 2022
- 121 Pages
Global
From €4536EUR$4,750USD£3,794GBP
From €3343EUR$3,500USD£2,795GBP
- Report
- September 2024
- 82 Pages
Japan
From €3343EUR$3,500USD£2,795GBP
- Report
- November 2023
- 183 Pages
Global
From €4298EUR$4,500USD£3,594GBP
- Report
- October 2023
- 81 Pages
United Kingdom
From €3343EUR$3,500USD£2,795GBP
- Report
- March 2023
- 111 Pages
Global
From €4298EUR$4,500USD£3,594GBP

The Prostate Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat prostate cancer. Prostate cancer is the most common cancer in men, and the drugs used to treat it can vary depending on the stage and severity of the disease. Common treatments include hormone therapy, chemotherapy, and radiation therapy.
The Prostate Cancer Drugs market is highly competitive, with many companies vying for market share. Major players in the market include Astellas Pharma, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are constantly researching and developing new drugs to treat prostate cancer, as well as improving existing treatments. Show Less Read more